HC Wainwright Has Pessimistic Outlook of SANA Q3 Earnings

Key Points

• HC Wainwright lowered its Q3 2026 earnings forecast for Sana Biotechnology to a loss of $0.14 per share from $0.13 previously, with projected losses continuing through later fiscal years.
• Sana’s latest quarterly loss of $0.13 per share beat analysts’ consensus estimate of a $0.15 loss, while the stock recently traded around $3.77 and remains well below its 52-week high of $6.55.
• Analyst sentiment is mixed but leans positive: MarketBeat reports a “Moderate Buy” consensus, a $9.50 average price target, and institutional investors own approximately 88.23% of the shares.

Sana Biotechnology, Inc. (NASDAQ:SANA - Free Report) - Analysts at HC Wainwright dropped their Q3 2026 earnings estimates for Sana Biotechnology in a report issued on Tuesday, August 11th. HC Wainwright analyst E. Bodnar now expects that the company will post earnings of ($0.14) per share for the quarter, down from their previous forecast of ($0.13). The consensus estimate for Sana Biotechnology's current full-year earnings is ($0.59) per share. HC Wainwright also issued estimates for Sana Biotechnology's Q4 2026 earnings at ($0.14) EPS, FY2026 earnings at ($0.54) EPS, FY2028 earnings at ($0.62) EPS, FY2029 earnings at ($0.62) EPS and FY2030 earnings at ($0.45) EPS.

A number of other analysts have also commented on the company. Weiss Ratings raised Sana Biotechnology from a "sell (e+)" rating to a "sell (d-)" rating in a research report on Thursday, July 23rd. Wall Street Zen lowered shares of Sana Biotechnology from a "hold" rating to a "sell" rating in a research note on Monday, July 20th. Finally, Rodman & Renshaw started coverage on shares of Sana Biotechnology in a research note on Monday, May 11th. They issued a "buy" rating and a $16.00 price objective on the stock. Seven investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $9.50.

Sana Biotechnology Trading Down 0.5%

SANA opened at $3.77 on Thursday. The company has a fifty day moving average price of $3.33 and a two-hundred day moving average price of $3.46. Sana Biotechnology has a 1-year low of $2.61 and a 1-year high of $6.55. The company has a market cap of $1.13 billion, a P/E ratio of -4.96 and a beta of 2.16.

Sana Biotechnology (NASDAQ:SANA - Get Free Report) last issued its earnings results on Tuesday, August 11th. The company reported ($0.13) earnings per share for the quarter, topping analysts' consensus estimates of ($0.15) by $0.02.

Institutional Investors Weigh In On Sana Biotechnology

Institutional investors have recently added to or reduced their stakes in the company. Walleye Capital LLC purchased a new stake in Sana Biotechnology during the second quarter worth about $35,000. Royal Bank of Canada increased its stake in shares of Sana Biotechnology by 76.8% during the 1st quarter. Royal Bank of Canada now owns 12,285 shares of the company's stock worth $35,000 after purchasing an additional 5,338 shares during the last quarter. Mercer Global Advisors Inc. ADV bought a new stake in shares of Sana Biotechnology in the 3rd quarter worth approximately $36,000. Rockefeller Capital Management L.P. lifted its stake in Sana Biotechnology by 74.3% in the fourth quarter. Rockefeller Capital Management L.P. now owns 9,588 shares of the company's stock valued at $39,000 after purchasing an additional 4,088 shares during the last quarter. Finally, Russell Investments Group Ltd. bought a new position in Sana Biotechnology during the third quarter valued at $39,000. 88.23% of the stock is owned by institutional investors.

Sana Biotechnology Company Profile

Sana Biotechnology is a clinical-stage biopharmaceutical company focused on the development of engineered cells as medicines with the goal of treating a broad range of diseases. The company applies advanced gene editing and gene delivery technologies to create next-generation cell therapy products for oncology, genetic disorders and other serious diseases. By leveraging both ex vivo and in vivo approaches, Sana aims to repair or replace damaged cells and restore healthy tissue function.

The company's core platform integrates proprietary gene writing capabilities alongside established gene editing tools such as CRISPR–Cas9.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source